Islet Management’s IGM Biosciences IGMS Stock Holding History

Islet Management’s Portfolio IGMS Stock Details IGMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-131,700	Closed	-$3.52M	–	142
2022 Q1	$3.52M	Buy	+131,700	New	+$2.45M	0.14%	94

Other funds holding IGMS

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Islet Management's IGMS Position: Q2 2022 in Review

Islet Management sold out of IGM Biosciences (IGMS) in Q2 2022, closing a stake of 131,700 shares — an estimated $3.52M sold.

Islet Management first reported a position in IGMS in Q1 2022 and held it in 1 quarter. The position peaked at $3.52M in Q1 2022. 89 funds tracked by Wall St. Rank hold IGMS as of Q2 2022.

Islet Management reported no remaining IGM Biosciences position as of Q2 2022 after selling out during the quarter.
Islet Management sold 131,700 IGM Biosciences shares in Q2 2022, an estimated $3.52M.
Islet Management first reported a position in IGM Biosciences in Q1 2022 and held it in 1 quarter.
Islet Management's IGM Biosciences position peaked at $3.52M in Q1 2022.
89 funds tracked by Wall St. Rank held IGM Biosciences as of Q2 2022.

Based on Islet Management's 13F filing for Q2 2022, filed 15 Aug 2022.